X

Gujarat Terce Laboratories Ltd Stock Analysis

Small Cap
Evaluated by 93 users | BSE: 524314 | NSE: |
Pharmaceuticals & Drugs
Gujarat Terce Laboratories is engaged in the manufacturing of tablets, capsules, syrup and injections pertaining to the product group, pharmaceutical formulations and ayurvedic medicines. The company is selling its product in the domestic as well as international market.The company’s...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 6.28%2.65%2.38%2.66%1.95%-2.23%1.18%2.4%5.48%3.79%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 35.998.77928.926.52525.3293137.5
Y-o-Y Gr. Rt.-175.1%-19.9%-63.5%-8.2%-5.6%1.2%14.7%7%21%
Adjusted EPS (Rs.) 0.560.190.250.320.12-0.91-0.020.240.580.37
Y-o-Y Gr. Rt.--66.1%31.6%28%-62.5%-858.3%NANA141.7%-36.2%
Book Value per Share (Rs.) 13.9914.1614.4214.7414.8713.9613.5514.0214.614.97
Adjusted Net Profit 0.40.10.20.20.1-0.700.20.40.3
Net Op. Cash Flow (Rs. Cr.) 2.2-940.51.40.20.24.6-0.6-1.6
Debt to Cash Flow from Ops 1.12-1.182.2819.045.9644.1328.990.08-1.11-1.63
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Gujarat Terce Laboratories Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 0.5%7.2%14.1%21%
Adjusted EPS -4.5%25.3%NA-36.2%
Book Value per Share 0.80.13.42.5
Share Price -6.8% -0.7% -14.2% 18.9%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 5.111.371.752.20.83-6.3-0.151.714.072.49
Operating Profit Margin (%) 3.560.881.223.312.940.660.321.111.571.82
Net Profit Margin (%) 1.160.150.230.830.34-2.7-0.060.61.390.73
Debt to Equity 0.241.010.850.80.740.690.70.040.060.23
Working Capital Days 1467079224247256246209196178
Cash Conversion Cycle 393050128145151146945960
Entity Percentage Holding
Promoters 35.74%
Non-Institutions 64.26%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Gujarat Terce Laboratories Ltd's performance infers:

Gujarat Terce Laboratories Ltd earnings have grown by 25.3%, whereas share price has depreciated -0.7% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Gujarat Terce Laboratories Ltd share prices over the last 10 years. Here is what we found out:

Gujarat Terce Laboratories Ltd share price has depreciated -6.2% annually over the past ten years.

Gujarat Terce Laboratories is engaged in the manufacturing of tablets, capsules, syrup and injections pertaining to the product group, pharmaceutical formulations and ayurvedic medicines. The company is selling its product in the domestic as well as international market.

The company’s registered office and factory are located at Bileshwarpura, Gandhinagar in Gujarat. Installed capacity of the company is 270 million tablets and 108 million capsules per annum.

Product list

Gujarat Terce Laboratories is engaged in the manufacturing of tablets, capsules, syrup and injections pertaining to the product group, pharmaceutical formulations and ayurvedic medicines. The company is selling its product in the domestic as well as international market.

The company’s registered office and factory are located at Bileshwarpura, Gandhinagar in Gujarat. Installed capacity of the company is 270 million tablets and 108 million capsules per annum.

Product list of the company includes:

  • Tablets
  • Capsules
  • Syrup
  • Injections
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
© 2021 MoneyWorks4me.com | All Rights Reserved